Search results
Results from the WOW.Com Content Network
An estimated 6.7 million Americans ages 65 and older were living with Alzheimer’s in 2023, according to the Alzheimer’s Association. The number is projected to increase to 13.8 million by 2060.
And 1 in 3 adults ages 65 and older dies with it or another form of dementia, according to the Alzheimer’s Association. Leqembi has been shown to successfully reduce amyloid plaques in the brain.
After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021.
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward ...
A panel of brain and Alzheimer’s experts convened by the U.S. Food and Drug Administration (FDA) voted unanimously on June 10 that a new Alzheimer’s drug developed by Eli Lilly, called ...
Results of a phase 3 clinical trial conducted at 235 different medical sites across North America, Europe, and Asia, that were published in the New England Journal of Medicine found that lecanemab ...
For each category, patients were rated on a 5-point scale: 0 is normal, 0.5 is questionable dementia and 1, 2 and 3 are mild, moderate and severe stages of dementia, respectively.
The Food and Drug Administration just approved pharmaceutical company Eli Lilly’s Alzheimer’s drug donanemab, following a clinical trial that showed the drug slowed Alzheimer’s progression ...